Correction of Adipocyte Secretion Disorders in Patients With Non-Alcoholic Fatty Liver Disease With Overweight and Obesity

Abstract

Introduction: The attention of scientists from many countries is focused on hormonal substances - adipokines at the present time. Lowering the level of the hormone adiponectin plays a central role in the development of obesity and cardiovascular disease in humans. The aim of the work is to determine the effect of complex therapy of thiotriazolin and L-lysine escinate on adipocyte secretion indices in patients with non-alcoholic fatty liver disease (NAFLD) with overweight and obesity. Materials and methods: 135 patients with overweight and obesity were examined, 46 of which were overweight (BMI-25-29.9 kg / m2), 34 were obesity grade I (BMI-30-34.9 kg / m2), 20 - Obesity II degree (BMI-35-39.9 kg / m2). 35 patients had normal body mass (BMI 18-24.9 kg / m2). We also examined 20 practically healthy persons. The age of the examinees varied, the median age was 55 years (intercourt scale Q1-Q3 from 40 to 61 years). The verification of the diagnosis of NAFLD was conducted in accordance withthe recommendations of the Unified Clinical Protocol. Results: The additional use of thiotriazolin and L-lysine escinate significantly influenced the adiponectin concentration level. Compared with the period before treatment, the adiponectin level increased in patients with overweight and obesity in 1,6 times (p <0.05). Compared to baseline, the adiponectin content in patients with NAFLD increased by 24.6-27.6% (p <0.05). Also, the level of leptin decreases significantly in patients with overweight and obesity (p <0.05). Conclusions: Integrated therapy with thiotriazolin and L-lysine escinate is an effective way to normalize the level of adipokines in patients with NAFLD with overweight and obesity.

Adipokines and Obesity. Potential Link to Metabolic Disorders and Chronic Complications

“…Until now, a lot of substances secreted by adipose tissue have been discovered and described, and their metabolic effects and contribution to the pathogenesis of civilization-related diseases are being extensively studied [39][40][41][42]. It is interesting that both obese and lipodystrophic patients show similar clinical disorders: hypertriglyceridemia, insulin resistance and fatty liver [43][44][45]. The disorders lead to diabetes, hypertension, polycystic ovary syndrome (PCOS), coronary artery disease (CAD) and cancers [45][46][47][48][49][50].…”

Endothelial Dysfunction in Non-Alcoholic Fatty Liver Disease

“…Adiponectin has also been shown to prevent endothelial apoptosis. We found that in patients with NAFLD with overweight and obesity, increased leptin levels, decreased serum adiponectin levels were associated with increased body mass index, insulin resistance, increased concentration of highly sensitive CRP [12].…”

Метаболічно-Асоційовані Захворювання Та Ожиріння

“…Свій вклад вносить і метаболічний статус [20,21] Ми виявили, що у пацієнтів з НАЖХП із надмірною масою тіла та ожирінням підвищення рівня лептину, зниження рівня адипонектину в сироватці крові мали зв'язок з підвищенням індексу маси тіла, інсулінорезистентністю [22]. При надмірній масі тіла проліферація та гіпертрофія адипоцитів супроводжується інфільтрацією макрофагами з подальшим розвитком запальних реакцій, внаслідок чого змінюється метаболічна активність жирової тканини [23,24].…”